Plasma Exchange Shows Promise for Liver Chemistry But Not Survival in Acute Liver Failure

Acute liver failure (ALF) is a devastating condition with mortality rates exceeding 60% without liver transplantation. This pilot randomized controlled trial investigated whether therapeutic plasma exchange (TPE) could improve outcomes by removing toxins and replacing clotting factors in critically ill patients.

Researchers at All India Institute of Medical Sciences randomized 40 ALF patients to receive either standard medical therapy alone or standard care plus daily TPE for up to 5 days. Most patients (57.5%) had viral hepatitis as the underlying cause, with a median age of 24 years. TPE involved removing patient plasma and replacing it with fresh frozen plasma and albumin.

The results revealed a striking disconnect between biochemical improvement and clinical outcomes. By day 3, TPE recipients showed significantly greater reductions in bilirubin (P=0.002), international normalized ratio or INR (P=0.013), and ammonia levels (P=0.340) compared to controls. These improvements suggest TPE effectively cleared toxins and corrected coagulation abnormalities.

However, these laboratory improvements didn't translate to survival benefits. Thirty-day mortality was identical at 65% in both groups, with similar rates of infections and complications. The lack of survival benefit persisted even when analyzing only patients who actually received TPE treatments.

These findings suggest that while TPE can rapidly improve liver function markers, it may not address the fundamental regenerative failure driving mortality in ALF. The study was limited by its small size and single-center design, highlighting the need for larger multicenter trials to definitively establish TPE's role in ALF management.